NCT02397447View on ClinicalTrials.gov

Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

Momordica charantia

Momordica Charantia: 2000 mg per day for three months

DRUG

Placebo

Placebo: 2000 mg per day for three months

Trial Locations (1)

44340

Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara

All Listed Sponsors

lead

University of Guadalajara

OTHER

NCT02397447 - Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion | Biotech Hunter | Biotech Hunter